News

Here's Why Viking Therapeutics Bounced Back Today

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

How does Viking’s oral obesity drug stand up to those of Eli Lilly and Novo?

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...
Applied Clinical Trials Online1d

Oral GLP-1/GIP Dual Agonist VK2735 Achieves Up to 12% Weight Loss in Phase II VENTURE Trial

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

VKTX stock tumbles 29% today — Viking Therapeutics weight-loss trial results fuel massive investor sell-off and market jitters

Viking Therapeutics (VKTX) shares crashed nearly 29% in todays trade after the companys much-anticipated weight-loss pill ...

Viking Therapeutics: Panic Creates Opportunity

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Viking Therapeutics shorts gain $0.5B amid selloff: report

Viking Therapeutics (VKTX) stock plunges and short sellers betting against the company gain $521M amid the selloff. Read more here.